Skip to main content

Serologicals to Acquire Ion Channel Cell Line Provider Cytomyx

NEW YORK, March 14 (GenomeWeb News) - Serologicals will acquire Cytomyx, a wholly owned subsidiary of Cytomyx Holdings, Serologicals said today.


"Through this acquisition, our drug-discovery business will expand their service offerings to include GPCRs, kinases, and ion channels, the top three most-important target classes today," said Serologicals president and CEO, David Dodd in a statement.


Cytomyx has 23 ion channel cell lines commercially available and more in its pipeline, said Serologicals.


Serologicals expects to complete the acquisition in the first quarter of 2006 and for the acquisition to be "slightly accretive" in fiscal year 2006.


Financial details were not provided.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.